
[0005] Chemotherapeutic agents can be administered in a combination therapy (*e.g.*, two or more different chemotherapeutic agents) to combat drug resistance and to increase efficacy. There is a need in the art for therapies, both single and combination therapies, for treating r/r lymphomas and r/r leukemias. Provided herein are solutions to these and other problems in the art by providing combination therapies that include Compound A to treat lymphomas and leukemias and r/r lymphomas and leukemias.

3. SUMMARY

[0006] Provided herein are methods of treating, preventing, or managing lymphoma or leukemia. In one aspect is a method of treating, preventing, or managing lymphoma or leukemia by administering to a subject in need thereof Compound A:




(A),

or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with an anti-CD20 antibody.

[0007] Further provided herein is a method of treating, preventing, or managing lymphoma or leukemia by administering to a subject in need thereof Compound A, or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof, in combination with ibrutinib, or a pharmaceutically acceptable salt or solvate thereof.

[0008] In another aspect are pharmaceutical compositions, dosage forms, and dosing regimens in connection with the above-described methods. In some embodiments, the pharmaceutical compositions may be prepared as medicaments for the treatment of any of the conditions described herein. In some embodiments, the pharmaceutical compositions may be prepared as medicaments for the prevention of any of the conditions described herein. In some embodiments, the pharmaceutical compositions may be prepared as medicaments for the management of any of the conditions described herein.


One aspect relates to the use of Compound A:



(A),

or a pharmaceutically acceptable salt or solvate thereof, in combination with an anticancer agent, wherein said anti-cancer agent is an anti-CD20 antibody, **wherein** the combination is useful to prepare a medicament for treating, preventing, or managing lymphoma or leukemia, wherein the anti-CD20 antibody is obinutuzumab.

Another aspect concerns the use of Compound A:




(A),

or a pharmaceutically acceptable salt or solvate thereof, in combination with obinutuzumab, or a pharmaceutically acceptable salt or solvate thereof, **wherein** the combination is useful to prepare a medicament for treating, preventing, or managing lymphoma or leukemia.

CLAIMS


1. Use of Compound A:



(A),

or a pharmaceutically acceptable salt or solvate thereof, in combination with an anticancer agent, wherein said anti-cancer agent is an anti-CD20 antibody, **wherein** the combination is useful to prepare a medicament for treating, preventing, or managing lymphoma or leukemia, wherein the anti-CD20 antibody is obinutuzumab.

2. Use of Compound A:



(A),

or a pharmaceutically acceptable salt or solvate thereof, in combination with obinutuzumab, or a pharmaceutically acceptable salt or solvate thereof, **wherein** the combination is useful to prepare a medicament for treating, preventing, or managing lymphoma or leukemia.

3. Use of claims 1 or 2, wherein said lymphoma is diffuse large B-cell lymphoma (DLBCL).

4. Use of claims 1 or 2, wherein said lymphoma is non-Hodgkin's lymphoma (NHL).

5. Use of claim 4, wherein said NHL is indolent.

6. Use of claim 5, wherein said indolent NHL is follicular lymphoma (FL).

7. Use of claim 4, wherein said NHL is aggressive.

8. Use of claims 1 or 2, wherein said lymphoma is primary CNS lymphoma (PCNSL).

9. Use of claims 1 or 2, wherein said leukemia is chronic lymphocytic lymphoma (CLL) or small lymphocytic lymphoma (SLL).

10. Use of claims 1 or 2, wherein said leukemia is CLL.

11. Use of claim 10, wherein said CLL comprises a 17p deletion or a p53 mutation.

12. Use of claim 11, wherein said CLL comprises a 17p deletion.

13. Use of claim 11 or 12, wherein said CLL comprises a p53 mutation.

14. Use of any one of claims 9 to 13, wherein said CLL is

relapsed/refractory (r/r) CLL.

15. Use of claim 14, wherein said r/r CLL is resistant to at least on anticancer agent or cancer therapy.

16. Use of claims 1 or 2, wherein said leukemia is SLL.

17. Use of claim 16, wherein said SLL is relapsed/refractory (r/r) SLL.

18. Use of claim 17, wherein said r/r SLL is resistant to at least one anticancer agent or cancer therapy.